Oral Biologics & Biosimilars Global Market is Booming Across the Globe and Witness Huge Growth By Key Players To 2033 | The Business Research Company

The oral biologics & biosimilars market size has grown exponentially in recent years. It will grow from $6471.49 billion in 2023 to $7788.01 billion in 2024 at a compound annual growth rate (CAGR) of 20.3%. The growth in the historic period can be attributed to increased collaboration and partnerships between market players for better insights, increased need for immunology, increased demand due for cost-effective manufacturing process, aging population, government initiatives, and the ability to command high prices.

The oral biologics & biosimilars market size is expected to see exponential growth in the next few years. It will grow to $16634.59 billion in 2028 at a compound annual growth rate (CAGR) of 20.9%. The growth in the forecast period can be attributed to robust research and development activities for development of oral biologics, lean towards pills over injections, adoption of unhealthy lifestyles, technological advances, ease of use of oral biologics, increase in healthcare access, reimbursement of biologics, rise in biosimilars, and rising prevalence of chronic diseases . Major trends in the forecast period include invest in the oral biologics market to benefit from potentially strong profit margins, shift to biologics, as the innovation rate is increasing in that field, develop microneedle injectors-based drugs to increase the bioavailability and eliminate side effects of subcutaneous route.

Market Overview -
Biologics are drugs made from living cells using highly complex technology, while biosimilars are created to function similarly to biologics but are not identical to biologics. The oral biologics and biosimilar market comprises biologics and biosimilar drugs taken orally for the targeted treatment of Alzheimer's, multiple sclerosis, HIV/AIDS, and other serious conditions and are used to treat chronic diseases such as diabetes, arthritis, and cancer.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=6830&type=smp

Surging Prevalence Of Chronic Diseases Fuels Growth In Oral Biologics And Biosimilar Market
The rising prevalence of chronic diseases such as arthritis, asthma, and cancer is expected to propel the growth of the oral biologics and biosimilar market. Long working hours, limited physical activity, and unhealthy eating and drinking habits contribute to the prevalence of chronic diseases, and biologics are increasingly used to treat these chronic diseases. Biologics stimulate the immune system's attack on cancer cells, aiding the body's natural defenses in getting rid of the disease-causing cells. According to a United Nations article, a US-based intergovernmental organization, by 2030, chronic diseases are predicted to account for 70% of all fatalities worldwide. It is anticipated that chronic disease will account for nearly 60% of all deaths worldwide. Therefore, the rise in the prevalence of chronic diseases is driving the growth of the biologics and biosimilar market.

Competitive Landscape -
Major companies operating in the oral biologics & biosimilars market report are Merck & Co. Inc., GlaxoSmithKline, Novo Nordisk, ALK-Abelló, Aimmune Therapeutics Inc., VIVUS Inc, Materia Medica Holding, VECTOR-MEDICA, Henlius, Innovent Biologics, Bio-Thera, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Shanghai Fosun Pharmaceuticals, Biocon, Dr.Reddy's, Mylan, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, BiosanaPharma, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Microgen, Geropharm, Valenta, NovaMedica, SynBio, Roche, Rani Therapeutics, Eli Lilly and Company, Emisphere Technologies Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Pfizer Inc., Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Altis Biologics, Cipla Medpro South Africa, Genzyme

Growing Trend Of Creating Insulin Biosimilars Drives Innovation In Oral Biologics And Biosimilar Market
The creation of new insulin biosimilar is a key trend gaining popularity in the oral biologics and biosimilar market. The key players operating in the oral biologics and biosimilar market are investing in creating a biosimilar copy of insulin to capture the market share. For instance, in November 2021, Biocon, an India-based biopharmaceutical company launched inter-changeable biosimilar insulin. These products help to control high blood sugar in pediatric patients with type 1 diabetes and adults with type 2 diabetes and are available in a vial and prefilled pen presentations. These are interchangeable for the reference brand, Lantus (insulin glargine), allowing for substitution at the pharmacy counter. Thus, companies in the oral biologics and biosimilar market are investing in the trend of developing biosimilar of insulin to gain profit.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-global-market-report

Key Segments -
The oral biologics & biosimilars market covered in this report is segmented -
1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors, Immunostimulants, GPCR Modulators, Other Tharpies
2) By Disease: Diabetes, Arthritis and Crohn's Disease, Cancer, Infectious Disease, Other Autoimmune Disease, Other Diseases
3) By Molecule Type: Vaccines, Proteins and Peptides, Monoclonal Antibodies, Other Molecule Types
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.